Does higher number of lymph nodes (LNs) excised during radical prostatectomy (RP) improve biochemical relapse-free survival (bRFS) in patients with pT2-3a/pN0 prostate cancer? This is an ASCO Meeting ...
PARIS, Sept 25 (Reuters) - Ipsen has submitted a six-month sustained version of its prostate cancer treatment Decapeptyl for marketing approval with European health authorities, the French drugmaker ...
This is a preview. Log in through your library . Abstract The effects of depot formulations of the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl (25 µg/day) for 30 days or LHRH ...
Once approved, Decapeptyl® 6-month formulation will be marketed by Debiopharm’s partners, such as Ipsen in most European Union countries. “This submission in Europe of our first 6-month-formulation ...
Ipsen (Euronext: FR0010259150; Paris: IPN) today announced the start of the filing process in Europe of the 6–month sustained release formulation of Decapeptyl ®, a luteinizing hormone releasing ...
PARIS, Oct 13 (Reuters) - Ipsen has completed the marketing approval registration in nine European countries for a six-month sustained version of prostate cancer treatment Decapeptyl, the French ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Triptorelin is a type of hormone therapy. You pronounce it as trip-toe-reh-lin. It is a treatment for breast cancer. You might have triptorelin for early breast cancer with other hormone treatments if ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback